Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Purdue Pharma LP | 359 |
| 2 | Boston Scientific Scimed Inc | 339 |
| 3 | Arena Pharmaceuticals Inc | 280 |
| 4 | Celgene Corp | 250 |
| 5 | Warsaw Orthopedic Inc | 212 |
| 6 | Janssen Pharmaceutica NV | 161 |
| 7 | Intra Cellular Therapies Inc | 156 |
| 8 | Siemens AG | 146 |
| 9 | F Hoffmann La Roche AG | 122 |
| 10 | University of California, San Diego | 120 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 11,025 |
| 2 | A61K | Medicinal preparations | 9,656 |
| 3 | C07D | Heterocyclic compounds | 6,540 |
| 4 | C07K | Peptides | 1,357 |
| 5 | G01N | Investigating / analysing materials | 1,178 |
| 6 | A61L | Sterilising / disinfecting materials | 1,034 |
| 7 | C07C | Acyclic and carbocyclic compounds | 1,017 |
| 8 | C08L | Polymer compositions (blends) | 868 |
| 9 | C12N | Microorganisms, enzymes | 819 |
| 10 | Y02A | Climate change adaptation | 618 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionMost-cited patents
Patents ranked by forward citations reveal the foundational inventions the field continues to build on.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Synergistic compositions containing ketanserin | 1990 | Janssen Pharmaceutica NV | 27 |
| Process for the dehydrogenative dimerization and/or polymerization of organic compounds with active hydrogen atoms using perketals | 1986 | Luperox GmbH | 7 |
| Process for preparing ketanserine | 1984 | RAVIZZA S.p.A. | 6 |
| Cyclic perketals and their use for cross-linking high density polyethylene | 1981 | ARGUS CHEMICAL CORPORATION | 6 |
| Composition comprising ketanserin and L-carnitine or an alkanoyl L-carnitine for the treatment of CRPS | 2001 | Sigma Tau Industrie Farmaceutiche Riunite SpA | 2 |
Where research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Neurotransmitter Receptor Influence on Behavior | 14 |
| 2 | Neuroscience and Neuropharmacology Research | 5 |
| 3 | Neuroscience of respiration and sleep | 5 |
| 4 | Receptor Mechanisms and Signaling | 5 |
| 5 | Cardiac electrophysiology and arrhythmias | 4 |
| 6 | Pain Mechanisms and Treatments | 4 |
| 7 | Psychedelics and Drug Studies | 4 |
| 8 | Asthma and respiratory diseases | 3 |
| 9 | Nicotinic Acetylcholine Receptors Study | 3 |
| 10 | Nitric Oxide and Endothelin Effects | 3 |
Technology trend analysis
Cypris uses AI to connect emerging research themes to IP activity, commercialization signals, and underexplored opportunity areas.
See Cypris in actionWho's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Gitte M. Knudsen | Rigshospitalet | 26 |
| 2 | Adair R.S. Santos | Universidade Federal de Santa Catarina | 17 |
| 3 | Richard A. Glennon | Virginia Commonwealth University Medical Center | 16 |
| 4 | Alberto J. Kaumann | Heinrich Heine University Düsseldorf | 12 |
| 5 | Ana Lúcia S. Rodrigues | Universidade Federal de Santa Catarina | 12 |
| 6 | Claus Svarer | Copenhagen University Hospital | 11 |
| 7 | A. Amery | KU Leuven | 10 |
| 8 | Guido Maura | Istituto di Farmacologia Traslazionale | 5 |
| 9 | Lars H. Pinborg | Rigshospitalet | 10 |
| 10 | Takafumi Nagatomo | Niigata University of Pharmacy and Medical and Life Sciences | 10 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| [3H]Ketanserin (R 41 468), a selective 3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution, and functional role. | 1982 | 1079 | Synthesis and biological activity |
| Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action | 1998 | 1030 | Schizophrenia research and treatment |
| Hallucinogens Recruit Specific Cortical 5-HT2A Receptor-Mediated Signaling Pathways to Affect Behavior | 2007 | 920 | Neurotransmitter Receptor Influence on Behavior |
| Endothelium-dependent relaxation of coronary arteries by noradrenaline and serotonin | 1983 | 850 | Nitric Oxide and Endothelin Effects |
| Receptor binding profile of R 41 468, A novel antagonist at 5-HT2 receptors | 1981 | 846 | Neurotransmitter Receptor Influence on Behavior |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular composition of Ketanserin?
Which organizations hold the most patents related to Ketanserin?
What are the primary research topics associated with Ketanserin studies?
What key patents describe Ketanserin's composition and synthesis?
What are the most cited foundational research papers on Ketanserin?